source
- Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcyWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 7d ago↗ source
- FDA sets May 1 decision date for uniQure's Huntington's disease gene therapy after year-long regulatory sagaThe U.S. Food and Drug Administration has accepted uniQure's biologics license application for its Huntington's disease gene therapy and placed it on the priority review track, with a May 1 target…